Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03193151 · ClinicalTrials.gov registry record
Diagnostic and Therapeutic Applications of Microarrays in Liver Transplantation
A clinical trial of Liver Dysfunction, sponsored by University of Alberta.
- Recruiting
- Registry status
- 300
- Enrollment target
- 15
- Study locations
NCT03193151: Recruiting study of Liver Dysfunction, sponsored by University of Alberta.
NCT03193151 is a study of Liver Dysfunction that is actively recruiting participants, run by University of Alberta. The registered enrollment target is 300 participants. The trial reports 15 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03193151, a study of Liver Dysfunction, is actively recruiting participants, sponsored by University of Alberta.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 15
- Study locations
Study Summary
INTERLIVER is a prospective observational study of the relationship of the molecular phenotype of 300 liver transplant biopsies to the histologic phenotype and the clinical features and outcomes. A segment of a biopsy performed as standard-of-care for indications, or by center protocol, will be used for gene expression study.
Primary Outcome
Based on the reference set, create molecular classifier that predicts antibody mediated and T cell mediated rejection for next 200 biopsies
Conditions Studied
Interventions
- PROCEDURE liver biopsy
Study Locations (15)
Other
- Centenary Institute of Cancer Medicine & Cell Biology, Royal Prince Alfred Hospital - Camperdown
- Dep. of Nephrology, Transplantation & Internal Med., Samodzielny Publiczny Szpital Kliniczny im. A. Mieleckiego - Katowice
- Independent Public Composite Regional Hospital - Szczecin
- Warsaw Medical University, Jesus the Child Clinical Hospital - Warsaw
- Warsaw Medical University, Independent Public Clinical Hospital - Warsaw
- Institute for Liver Science, King's College London - London
California
- University of California San Francisco, Transplant Research Unit - San Francisco
Illinois
- Northwestern Memorial Hospital - Chicago
Maryland
- University of Maryland School of Medicine - Baltimore
Michigan
- Henry Ford Transplant Institute - Detroit
Tennessee
- Vanderbilt University Medical Center, Vanderbilt Transplant Center - Nashville
Texas
- Baylor University Medical Center, Annette C. and Harold C. Simmons Transplant Institute - Dallas
Virginia
- Transplant Surgery, VCU Medical Center - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2017-12-19 |
| Est. Completion | 2027-12 |
What NCT03193151 shows while recruiting
NCT03193151 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Liver Dysfunction appearing as the primary indexed condition, and to 1 intervention - of which liver biopsy is the first listed.
NCT03193151 lists 15 locations in 10 states (Other, California, Illinois).
Frequently Asked Questions
What is clinical trial NCT03193151 about?
NCT03193151 is a clinical study titled "Diagnostic and Therapeutic Applications of Microarrays in Liver Transplantation". INTERLIVER is a prospective observational study of the relationship of the molecular phenotype of 300 liver transplant biopsies to the histologic phenotype and the clinical features and outcomes. A segment of a biopsy performed as standard-of-care for indications, or by center protocol, will be used...
What is the current status of trial NCT03193151?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2017-12-19. Estimated completion is 2027-12.
What conditions does trial NCT03193151 study?
This clinical trial studies the following conditions: Liver Dysfunction.
What interventions are being tested in trial NCT03193151?
The interventions under investigation include: liver biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT03193151?
This trial is sponsored by University of Alberta, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03193151 being conducted?
This trial has 15 study locations across California, Illinois, Maryland, Michigan, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Dysfunction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI